Neuroprotective role of adenosine in the CNS

Polish Journal of Pharmacology

Volumn 54, Issue 4, 2002, Pages 313-326

  Wardas, Jadwiga ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adenosine; Adenosine A1 receptors; Adenosine A2A receptors; Excitotoxicity; Ischemia; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 CHLOROADENOSINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 AMINO 8 CHLORO 1 PHENYL 1,2,4 TRIAZOLO[4,3 A]QUINOXALINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5' AMINO 5' DEOXYADENOSINE; 6 N CYCLOPENTYLADENOSINE; 8 (3 CHLOROSTYRYL)CAFFEINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYLTHEOPHYLLINE; 9 (2 HYDROXY 3 NONYL)ADENINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE DEAMINASE; ADENOSINE KINASE INHIBITOR; CAFFEINE; CALCIUM ION; CGS 216800; CYCLOHEXYLADENOSINE; EXCITATORY AMINO ACID; GLUTAMIC ACID; METHAMPHETAMINE; OXIDOPAMINE; PHENYLISOPROPYLADENOSINE; THEOPHYLLINE; UNINDEXED DRUG; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; NEUROPROTECTIVE AGENT;

ANIMAL MODEL; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGRADATION KINETICS; EXTRACELLULAR FLUID; HYPOXIA; INHIBITION KINETICS; MOTOR DYSFUNCTION; MOUSE; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE CONDUCTION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; RAT; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PHYSIOLOGY;

ADENOSINE; ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; NEUROPROTECTIVE AGENTS; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1;

EID: 0036382165     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. 3 receptors and viability of astrocytes. Drug Dev. Res., 1998, 45, 379-386.
2. L: studies in human astroglioma cells. Biochem. Biophys. Res. Commun., 1997, 241, 297-304.
3. 2+ influx. Brit. J. Pharmacol., 1989, 98, 225-235.
4. Arvin B., Neville L.F., Roberts P.J.: 2-Chloroadenosine prevents kainic acid-induced toxicity in rat striatum. Neurosci. Lett., 1988, 93, 336-340.
5. Barth A., Newell D.W., Nguyen L.B., Winn H.R., Wender R., Meno J.R., Janigro D.: Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide. Brain Res., 1997, 762, 79-88.
6. 1 adenosine antagonist: an anatomical and behavioral study. Neuroscience, 1992, 48, 807-812.
7. Bona E., Aden U., Gilland E., Fredholm B.B., Hagberg H.: Neonatal cerebral hypoxia-ischemia: the effect of adenosine receptor antagonists. Neuropharmacology, 1997, 36, 1327-1338.
8. 2A adenosine receptors deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci., 1999, 19, 9192-9200.
9. 2A adenosine receptor inactivation in the MPTP model of Parkinson's disease. Soc. Neurosci. Abs., 2000, 26, 1291 (478.1).
10. Cronstein B.N., Levin R.I., Belanoff J., Weissmann G., Hirschhorn R.: Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest., 1986, 78, 760-770.
11. Daval J.-L., Nicolas F.: Opposite effects of cyclohexyl-adenosine and theophylline on hypoxic damage in cultured neurons. Neurosci. Lett., 1994, 175, 114-116.
12. DeLeo J., Schubert P., Kreutzberg G.W.: Propentophylline (HWA 285) protects hippocampal neurons of mongolian gerbils against ischemic damage in the presence of an adenosine antagonist. Neurosci. Lett., 1988, 84, 307-311.
13. DeLeo J., Schubert P., Kreutzberg G.W.: Protection against ischemic brain damage using propentophylline in gerbils. Stroke, 1988, 19, 1535-1539.
14. DelleDonne K.T., Sonsalla P.K.: Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther., 1994, 271, 1320-1326.
15. De Mendonça A., Sebastiǎo A.M., Ribeiro J.A.: Adenosine: does it have a neuroprotective role after all? Brain Res. Rev., 2000, 33, 258-274.
16. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C.: Tissue distribution of adenosine receptor mRNAs in the rat. Brit. J. Pharmacol., 1996, 118, 1461-1468.
17. Domenici M.R., de Carolis A.S., Sagratella S.: Block by N6-L-phenylisopropyl-adenosine of the electrophysiological and morphological correlates of hippocampal ischaemic injury in the gerbil. Brit. J. Pharmacol., 1996, 118, 1551-1557.
18. 1 receptor-mediated responses in rat hippocampus. J. Neurosci., 1997, 17, 607-614.
19. Dux E., Fastbom J., Ungerstedt U., Rudolphi K., Fredholm B.B.: Protective effect of adenosine and a novel xanthine derivative propentophylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res., 1990, 516, 248-256.
20. Dux E., Schubert P., Kreutzberg G.W.: Ultrastructural localization of calcium in ischemic hippocampal slices: the influence of adenosine and theophylline. J. Cerebr. Blood Flow Metabol., 1992, 12, 520-524.
21. Evans M.C., Swan J.H., Meldrum B.S.: An adenosine analogue, 2-chloroadenosine, protects against long-term development of ischemic cell loss in the rat hippocampus. Neurosci. Lett., 1987, 287-292.
22. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K.: Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci., 1997, 20, 482-486.
23. 2 dopamine receptors in rat striatum. Mol. Brain Res., 1992, 14, 186-190.
24. Finn S.F., Swartz K.J., Beal M.F.: 2-Chloroadenosine attenuates NMDA, kainate and quisqualate toxicity. Neurosci. Lett., 1991, 126, 191-194.
25. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Linden J., Stiles G.L.: Adenosine receptors. In: IUPHAR Compendium of Receptor Characterization and Classification. IUPHAR Media, London, 1998, 48 -57.
26. Fuji K., Hiramatsu M., Kameyama T, Nabeshima T.: Effects of repeated administration of propentophylline on memory impairment produced by basal forebrain lesion in rats. Eur. J. Pharmacol., 1993, 236, 411-417.
27. 2 receptor antagonist, reduces cerebral ischemic injury in the mongolian gerbil. Life Sci., 1994, 55, PL61-65.
28. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J. Jr., Sibley D.R.: D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 1990, 250, 1429-1432.
29. Gidday J.M., Fitzgibbons J.C., Shah A.R., Gonzales E.R., Park T.S.: Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine. Pediat. Res., 1995, 38, 306-311.
30. Goldberg M.P., Monyer H., Weiss J.H., Choi D.W.: Adenosine reduces cortical neuronal injury induced by oxygen or glucose deprivation in vitro. Neurosci. Lett., 1988, 89, 323-327.
31. 6-2-(4-aminophenyl) ethyladenosine (APNEA), a putative adenosine A3 receptor agonist, enhances methamphetamine-induced dopamine outflow in rat striatum. Pol. J. Pharmacol., 1998, 50, 299-305.
32. 2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res., 1998, 806, 202-209.
33. Gołembiowska K., Zylewska A.: Effect of adenosine kinase, adenosine deaminase and transport inhibitors on striatal dopamine and stereotypy after methamphetamine administration. Neuropharmacology, 2000, 39, 2124-2132.
34. Heron A., Lekieffre D., Le Peillet E., Lasbennes F., Seylaz J., Plotkine M., Boulu R.G.: Effects of an A1 adenosine receptor agonist on the neurochemical, behavioral and histological consequences of ischemia. Brain Res., 1994, 641, 217-224.
35. Higashi H., Marwaha A.S., Memo J.R., Winn H.R.: Correlation between hippocampal injury and neurobehavior following normo- and hyperglycemic cerebral ischemia, effect of theophylline and ZM241385. Drug Dev. Res., 2000, 50, 71, 092.
36. Hsu S.S.-F., Newell D.W., Tucker A., Malouf A.T., Winn H.R.: Adenosinergic modulation of CA1 neuronal tolerance to glucose deprivation in organotypic hippocampal cultures. Neurosci. Lett., 1994, 178, 189-192.
37. 2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem., 2002, 80, 262-270.
38. Impagnatiello F., Bastia E., Ongini E., Monopoli A.: Adenosine receptors in neurological disorders. Emerg. Ther. Targets, 2000, 4, 635-664.
39. Jacobson K.A., Von Lubitz D.K.J.E., Daly J.W., Fredholm B.B.: Adenosine receptor ligands: differences with acute versus chronic treatment. Trends. Pharmacol. Sci., 1996, 17, 108-113.
40. Jarrot D.M., Domer F.R.: A gerbil model of cerebral ischemia suitable for drug evaluation. Stroke, 1980, 11, 203-209.
41. 3H]CGS 21680. Eur. J. Pharmacol., 1989, 168, 243-246.
42. Jiang N., Kowaluk E.A., Lee C.-H., Mazdiyasni H., Chop M.: Adenosine kinase inhibition protects brain against transient focal ischemia in rats. Eur. J. Pharmacol., 1997, 320, 131-137.
43. Johnson M.P., McCarty D.R., Chmielewski P.A.: Temporal dependent neuroprotection with propentophylline (HWA 285) in a temporary focal ischemia model. Eur. J. Pharmacol., 1998, 346, 151-157.
44. 2A receptor agonists and antagonists. Neuroscience, 1998, 85, 229-237.
45. 2A receptor antagonist. Brain Res., 1998, 800, 328-335.
46. Kano T., Katayama Y., Kawamata T., Hirota H., Tsubokawa T.: Propentofylline administered by microdialysis attenuates ischemia-induced hippocampal damage but not excitatory amino acid release in gerbils. Brain Res., 1994, 641, 149-154.
47. Kolvenbach R., Figge C., Godehardt E., Sandmann W.: Adenosine agonists and global cerebral ischaemia. Brit. J. Clin. Pharmacol., 1993, 36, 134-135.
48. Larsen A.K., Osborne N.N.: Involvement of adenosine in retinal ischemia: studies on the rat. Invest. Ophthalmol. Visual Sci., 1996, 37, 2603-2611.
49. 1 agonist. J. Neurochem., 1993, 60, 768-771.
50. Li B., Rosenbaum P.S., Jennings N.M., Maxwell K.M., Roth S.: Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat. Exp. Eye Res., 1999, 68, 9-17.
51. Lin Y., Phillis J.W.: Deoxycoformycin and oxypurinol: protection against focal ischemic brain injury in the rat brain. Brain Res., 1992, 571, 272-280.
52. Lobner D., Choi D.W.: Dipyridamole increases oxygen-glucose deprivation-induced injury in cortical cell culture. Stroke, 1994, 25, 2085-2090.
53. Longo R., Zeng Y.C., Sagratella S.: Opposite modulation of 4-aminopyridine and hypoxic hyperexcitability by A1 and A2 adenosine receptor ligands in rat hippocampal slices. Neurosci. Lett., 1995, 200, 21-24.
54. Lynch J.J., Alexander K.M., Jarvis M.F., Kowaluk E.A.: Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures. Neurosci. Lett., 1998, 252, 207-210.
55. MacGregor D.G., Graham D.I., Jones P.A., Stone T.W.: Protection by an adenosine analogue against kainate-induced extrahippocampal neuropathology. Gen. Pharmacol., 1998, 31, 233-238.
56. MacGregor D.G., Graham D.I., Stone T.W.: The attenuation of kainate-induced neurotoxicity by chlormethiazole and its enhancement by dizocilpine, muscimol, and adenosine receptor agonists. Exp. Neurol., 1997, 148, 110-123.
57. MacGregor D.G., Jones P.A., Maxwell W.L., Graham D.I., Stone T.W.: Prevention by a purine analogue of kainate-induced neuropathology in rat hippocampus. Brain Res., 1996, 725, 115-120.
58. 1 receptor. Br. J. Pharmacol., 1993, 110, 470-476.
59. MacGregor D.G., Stone T.W.: Prevention of kainate-induced excitotoxicity by a purine analogue. Neuroreport, 1992, 3, 536-538.
60. 6-phenylisopropyladenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration. Br. J. Pharmacol., 1993, 109, 316-321.
61. MacGregor D.G., Stone T.W.: Blockade by 1,3-dipropyl-8-cyclopentylxanthine (CPX) of purine protection against kainate neurotoxicity. Brain Res., 1994, 644, 339-342.
62. Martin R.L., Lloyd H.G.E., Cowan A.I.: The early events of oxygen and glucose deprivations: setting the scene for neuronal death? Trends Neurosci., 1994, 17, 251-257.
63. Matias A., Zimmer F.J., Lorenzen A., Keil R., Schwabe U.: Affinity of central adenosine A1 receptors is decreased in spontaneously hypertensive rats. Eur. J. Pharmacol. Mol. Pharmacol. Sect., 1993, 244, 223-230.
64. Matsumoto K., Sakaki T., Kohmura E., Hayakawa T., Yamada K.: Amelioration of ischemic brain damage by the preischemic administration of propentophylline (HWA285) in a rat focal ischemia. Brain Res., 1996, 723, 228-230.
65. Matsuoka Y., Okazaki M., Takata K., Kitamura Y., Ohta S., Sekino Y., Taniguchi T.: Endogenous adenosine protects CA1 neurons from kainic acid-induced neuronal loss in the rat hippocampus. Eur. J. Neurosci., 1999, 11, 3617-3625.
66. Miller L.P., Jelovich L.A., Yao L., DaRe J., Ugarkar B., Foster A.C.: Pre- and peristroke treatment with the adenosine kinase inhibitor, 5′-deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Neurosci. Lett., 1996, 220, 73-76.
67. 2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuro Report, 1998, 9, 3955-3959.
68. 2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotoxicity Res., 2001, 3, 545-556.
69. Mori M., Nishizaki T., Okada Y.: Protective effect of adenosine on the anoxic damage of hippocampal slice. Neuroscience, 1992, 46, 301-307.
70. Newman G.C., Hospod F.E., Trowbridge S.D., Motwani S., Liu Y.: Restoring adenine nucleotides in a brain slice model of cerebral reperfusion. J. Cerebr. Blood Flow Metabol., 1998, 18, 675-685.
71. Olah M., Stiles G.L.: The role of receptor structure in determining adenosine receptor activity. Pharmacol. Ther., 2000, 85, 55-75.
72. 2A receptors and neuroprotection. Ann. NY Acad. Sci., 1997, 825, 30-48.
73. 2A receptors. Trends Pharmacol. Sci., 1996, 17, 364-372.
74. 2A adenosine receptors: an apparent paradox. Drug Dev. Res., 1998, 45, 387-393.
75. O'Regan M.H., Simpson R.E., Perkins L.M., Phillis J.W.: The selective A2 agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci. Lett., 1992, 138, 169-172.
76. Ostwald P., Park S.S., Toledano A.Y., Roth S.: Adenosine receptor blockade and nitric oxide synthase inhibition in the retina: impact upon post-ischemic hyperemia and the electroretinogram. Vision Res., 1997, 37, 3453-3461.
77. Park C.K., Rudolphi K.A.: Antiischemic effects of propentophylline (HWA285) against focal cerebral infarction in rats. Neurosci. Lett., 1994, 178, 235-238.
78. Phillis J.W.: Adenosine in the control of the cerebral circulation. Cerebrovasc. Brain Metab. Rev., 1989, 1, 26-54.
79. 2a adenosine receptor antagonists on cerebral ischemia injury in the gerbil. Brain Res., 1995, 705, 79-84.
80. Phillis J.W., O'Regan M.H.: Deoxycoformycin prevents ischemia-induced locomotor hyperactivity in the unanesthetized gerbil. Med. Sci., Res., 1988, 16, 897-898.
81. Phillis J.W., O'Regan M.H.: Deoxycoformycin antagonizes ischemia-induced neuronal degeneration. Brain Res. Bull., 1989, 22, 537-540.
82. Phillis J.W., Smith-Barbour M.: The adenosine kinase inhibitor, 5-iodotubercidin, is not protective against cerebral ischemic injury in the gerbil. Life Sci., 1993, 53, 497-502.
83. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol., 1995, 287, 215-217.
84. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci., 1997, 18, 338-344.
85. 2A receptors in the rat central nervous system. J. Comp. Neurol., 1998, 401, 163-186.
86. Rothman S.: Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J. Neurosci., 1984, 4, 1884-1891.
87. Roussel S., Pinard E., Seylaz J.: Focal cerebral ischemia in chronic hypertension: no protection by (R)-phenylisopropyladenosine. Brain Res., 1991, 545, 171-174.
88. 1) receptors by caffeine treatment. Neurosci. Lett., 1989, 103, 275-280.
89. Rudolphi K.A., Keil M., Hinze H.-J.: Effect of theophylline on ischemically induced hippocampal damage in mongolian gerbils: a behavioral and histopathological study. J. Cerebr. Blood Flow Metabol., 1987, 7, 74-81.
90. Rudolphi K.A., Schubert P.: Modulation of neuronal and glial cell function by adenosine and neuroprotection in vascular dementia. Behav. Brain Res., 1997, 83, 123-128.
91. Rudolphi K., Schubert P., Parkinson F.E., Fredholm B.B.: Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci., 1992, 13, 439-445.
92. Schiffmann S.N., Jacobs O., Vanderhaeghen J.J.: The striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons. An in situ hybridization histochemistry study. J. Neurochem., 1991, 57, 1062-1067.
93. Sebastiao A.M., Ribeiro J.A.: Fine-tuning neuro-modulation by adenosine. Trends Pharmacol Sci., 2000, 21, 341-346.
94. 2A receptor-mediated excitatory actions on the nervous system. Prog. Neurobiol., 1996, 48, 167-189.
95. 2A receptor agonist CGS 21680. Drug Dev. Res., 1996, 39, 108-114.
96. Simon R.P., Swan J.H., Griffiths T., Meldrum B.S.: Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science, 1984, 226, 850-852.
97. Simpson R.E., O'Regan M.H., Perkins L.M., Phillis J.W.: Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists. J. Neurochem., 1992, 58, 1683-1690.
98. Stone T.W., Behan W.M.H.: Adenosine receptors, kynurenines and neuroprotection. Drug Dev. Res., 2000, 50, 15, S07-03.
99. Sturm C.D., Frisella W.A., Yoon K.-W.: Attenuation of potassium cyanide-mediated neuronal cell death by adenosine. J. Neurosurg., 1993, 79, 111-115.
100. Sutherland G.R., Peeling J., Lesiuk H.J., Brownstone R.M., Rydzy M., Saunders J.K., Geiger J.D.: The effects of caffeine on ischemic neuronal injury as determined by magnetic resonance imaging and histopathology. Neuroscience, 1991, 42, 171-182.
101. Svenningsson P., Hall H., Sedvall G., Fredholm B.B.: Distribution of adenosine receptors in the post-mortem human brain: an extended autoradiographic study. Synapse, 1997, 27, 322-335.
102. Tatlisumak T., Takano K., Carano R.A.D., Miller L.P., Foster A.C., Fisher M.: Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke, 1998, 29, 1952-1958.
103. Thorn J.A., Jarvis S.M.: Adenosine transporters. Gen. Pharmacol., 1996, 27, 613-620.
104. Uchino S., Nakamura T., Nakamura K., Nakajima-Iijima S., Mishina M., Kohsaka S., Kudo Y.: Real-time, two-dimensional visualization of ischaemia-induced glutamate release from hippocampal slices. Eur. J. Neurosci., 2001, 13, 670-678.
105. Von Lubitz D.K.J.E.: Adenosine and cerebral ischemia: therapeutic future or death of a brave concept. Eur. J. Pharmacol., 1999, 365, 9-25.
106. Von Lubitz D.K.J.E., Dambrosia J.M., Kempski O., Redmond D.J.: Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of gerbil hippocampus. Stroke, 1988, 19, 1133-1139.
107. Von Lubitz D.K.J.E., Dambrosia J.M., Redmond D.J.: Protective effect of cyclohexyl adenosine in treatment of cerebral ischemia in gerbils. Neuroscience, 1989, 30, 451-462.
108. Von Lubitz D.K.J.E., Kim J., Beenhakker M., Carter M.F., Lin R.C.-S., Meshulam Y., Daly J.W., Shi D., Zhou L.-M., Jacobson K.A.: Chronic NMDA receptor stimulation: therapeutic implications of its effect on adenosine A1 receptors. Eur. J. Pharmacol., 1995, 283, 185-192.
109. 3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur J. Pharmacol., 1999, 367, 157-163.
110. 2A receptor agonist and antagonist. Eur. J. Pharmacol., 1995, 287, 295-302.
111. Von Lubitz D.K.J.E., Lin R.C.-S., Melman N., Ji X.-D., Carter M.F., Jacobson K.A.: Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur. J. Pharmacol., 1994, 256, 161-167.
112. Von Lubitz D.K.J.E., Lin R.C.-S., Paul I.A., Beenhakker M., Boyd M., Bischolberger N., Jacobson K.A.: Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur. J. Pharmacol., 1996, 316, 171-179.
113. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol., 1994, 263, 59-67.
114. Von Lubitz D.K.J.E., Marangos P.J.: Cerebral ischemia in gerbils: postischemic administration of cyclohexyl adenosine and 8-sulphohenyl-theophylline. J. Mol. Neurosci., 1990, 2, 53-59.
115. 2A adenosine receptor antagonist, counteracts the parkinsonian-like muscle rigidity in rats. Synapse, 2001, 41, 160-171.
116. Zhou Q.-Y., Meno J.R., Hsu S.S.-F., Winn H.R.: Effects of theophylline and cyclohexyladenosine on brain injury following normo- and hyperglycemic ischemia: a histopathologic study in the rat. J. Cerebr. Blood Flow Metabol., 1994, 14, 166-173.
117. Zimmermann H., Braun N., Nocken F.: Extracellular hydrolysis of ATP and formation of adenosine in the nervous system. In: Adenosine and Adenine Nucleotides: from Molecular Biology to Integrative Physiology. Eds. Belardinelli L., Pelleg A., Kluwer Acad. Publ., Boston, 1995, 179-187.